These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
93 related items for PubMed ID: 2118285
1. Clinical importance of prostatic measurements in follow-up of GnRH analogue-treated prostatic carcinoma patients. Matzkin H, Greenstein A, Braf Z. Urology; 1990 Sep; 36(3):214-8. PubMed ID: 2118285 [Abstract] [Full Text] [Related]
2. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience. Matzkin H, Greenstein A, Kaver I, Braf Z. Isr J Med Sci; 1989 Jul; 25(7):388-92. PubMed ID: 2474522 [Abstract] [Full Text] [Related]
3. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study. Pettersson B, Varenhorst E, Petas A, Sandow J. Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856 [Abstract] [Full Text] [Related]
4. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results. Borgmann V, al-Abadi H, Nagel R. Am J Clin Oncol; 1988 Sep; 11 Suppl 1():S19-28. PubMed ID: 2968759 [Abstract] [Full Text] [Related]
5. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R. N Engl J Med; 1989 Aug 17; 321(7):413-8. PubMed ID: 2503723 [Abstract] [Full Text] [Related]
6. Transabdominal ultrasonography in the evaluation of patients with advanced prostatic carcinoma: effects of castration and of chronic administration of a gonadotropin releasing hormone agonistic analogue. Tolis G, Koutsilieris M, Fazekas AT, Patton R. Prostate; 1983 Aug 17; 4(6):595-600. PubMed ID: 6415631 [Abstract] [Full Text] [Related]
7. Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. Siegel YI, Korczak D, Lindner A. Eur Urol; 1991 Aug 17; 19(1):16-8. PubMed ID: 1901042 [Abstract] [Full Text] [Related]
8. Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life. Presant CA, Soloway MS, Klioze SS, Yakabow A, Presant SN, Mendez RG, Kennedy PS, Wyres MR, Naessig VL, Todd B. Cancer; 1987 May 15; 59(10):1713-6. PubMed ID: 3103904 [Abstract] [Full Text] [Related]
9. Kinetic evaluation of the effect of LHRH analog on prostatic cancer using transrectal ultrasonotomography. Kojima M, Watanabe H, Ohe H, Miyashita H, Inaba T. Prostate; 1987 May 15; 10(1):11-7. PubMed ID: 3103113 [Abstract] [Full Text] [Related]